DEVELOPMENT AND APPLICATION OF NANOSCIENCE AND NANOTECHNOLOGY TO HEART, LUNG, AND BLOOD DISEASES, AND SLEEP DISORDERS RELEASE DATE: December 4, 2002 NOTICE: NOT-HL-03-005 National Heart, Lung, and Blood Institute (NHLBI) (http://www.nhlbi.nih.gov/) Response Due Date: January 24, 2003 PURPOSE The NHLBI is soliciting comments and ideas on approaches to develop and apply nanotechnology and nanoscience to the study, diagnosis, treatment, and prevention of cardiovascular, pulmonary, blood, and sleep disorders. BACKGROUND Nanoscience and nanotechnology are rapidly growing fields with significant potential to provide a new generation of scientific and technological approaches and of research and clinical tools and devices. The essence of nanoscience and nanotechnology is the creation and use of molecules, molecular assemblies, materials, and devices in the range of 1-100 nm, and the exploitation of the unique properties and phenomena of matter at this dimensional scale. Nanotechnology comprises both top-down and bottom-up fabrication methodologies. In the former, nanoscale devices and their components draw inspiration from larger, currently known devices and components, while the latter pertains to the assembly of devices from individual atoms, molecules, and supramolecular structures of biological and synthetic origins. In terms of heart, lung, blood, and sleep disorders, diagnostics, therapeutics, and biosensors are likely to be among the earliest applications of nanotechnology to become clinically important. Furthermore, the use of nanoparticles opens new opportunities for localized targeting and controlled release of drugs and gene delivery. Nanotechnology also provides new approaches for noninvasive molecular imaging, which may lead to advances in understanding the mechanisms of health and disease. An additional area is the use of nanotechnology to develop biomimetic materials for use in tissue engineering. An overarching vision that may be enabled by nanotechnology includes the development of systems that comprise intelligently linked diagnostics and therapeutic functions on a single, implanted or injected, multifunctional device. While the individual functional components of such a device would be on a nanoscale, the entire device itself might be larger. In this context, nanotechnology may provide innovative solutions to the problem of in-vivo targeting. Of interest is the development of 'smart' systems for the release of therapeutic agents, where 'smart' refers to any combination of the following capabilities, in surgically implanted, injected, inhaled, and orally, or otherwise administered devices: o Concentration of therapeutic action exclusively or predominantly at a desired target site; o Avoidance of biological and biophysical barriers to the penetration and efficacy of the therapeutic action; o Release of therapeutic action in desired, pre-programmed time-dependent patterns; o Operator-controlled, remotely activated release of a therapeutic agent. In a scenario of interest, the in-vivo nanodevice would sense and relay information to the attending medical personnel, who would then regulate the release of a therapeutic agent; o Self-regulated release of therapeutic action, from a device comprising sensors of appropriate biomarkers, release technology, and on-board intelligence connecting these functions. Some examples of specific, broad areas of interest for application of nanotechnology include clinical scenarios involving inflammatory processes, fibrosis, and tissue damage and repair. However, interest is not limited to these areas only. Systems that may provide the above-listed combination of nanotechnology-enabled functionalities include: o Molecular assemblies or particulates for diagnostic imaging (smart contrast agents) and targeted therapeutics; o Molecular assemblies capable of targeted release; o Implantable systems for controlled actions, including drug release chips and stents; o Substrates and templates for organ and/or tissue repair; o Circulating or implantable hybrids comprising biological cells and synthetic elements for tracking, imaging and therapeutics; o In-vivo assessments, including mechano-chemical sensing technology; o Molecular assemblies that can be addressed externally by application of a magnetic or electrical field, sound waves, radiation, etc. INFORMATION REQUESTED The NHLBI seeks your help in identifying (a) the major opportunities in developing and applying nanoscience and nanotechnology to heart, lung, blood, and sleep research and medicine; (b) the critical needs to enable progress and the barriers that may inhibit it; and (c) practical and effective ways to meet the needs, overcome the barriers, and take full advantage of the opportunities. Your thoughts, ideas, and suggestions will be used to help guide future Institute activities designed to expedite the development and application of nanoscience and nanotechnology to biological research questions and efforts to improve patient care. Respondents are asked to comment on one or more of the issues listed below, but should not feel compelled to address all of them. 1. Please comment on what you view as the major opportunities for developing and applying nanotechnology and nanoscience to heart, lung, blood, and sleep research and medicine. Please suggest areas that are particularly promising and are of highest priority. 2. Please identify the major needs for and barriers to developing and applying nanotechnology and nanoscience to heart, lung, blood, and sleep research and medicine. 3. Please suggest approaches the NHLBI can take to meet the needs, overcome the barriers, and take full advantage of the opportunities. Any specific suggestions and general estimates of associated costs would be valuable. 4. Please consider and comment on regulatory issues that are likely to be encountered in applying nanotechnology to NHLBI-supported research (e.g., need for coincident approval for novel imaging agents with the corresponding instrumentation). Please include ideas on how these issues can be overcome. 5. Please provide other examples of nanoscience and nanotechnology, real or imaginary that might be suggested for application to heart, lung, blood, and sleep research and medicine. 6. We would appreciate any additional views or opinions that you think would be useful. RESPONSE AND PROCESS Responses in any of the areas are welcome; respondents should not feel compelled to address all items. Please respond no later than January 24, 2003. Responses will be compiled and shared with our advisory committees. We look forward to your thoughts, opinions, and suggestions and hope you will share this document with your colleagues. Thank you very much for your help. To respond, please link to the online form in the What's New section on the NHLBI Home Page (http://www.nhlbi.nih.gov/funding/inits/nanorfi.htm), or send a letter, fax, or e-mail to the following address: Tawanna Meadows Two Rockledge Centre 6701 Rockledge Drive Room 9163, MSC 7940 Bethesda, MD 20892-7940 Telephone: (301) 435-1802 FAX: (301) 480-1335 E-mail: NHLBINano@nhlbi.nih.gov
Return to NIH Guide Main Index
Office of Extramural Research (OER) |
National Institutes of Health (NIH) 9000 Rockville Pike Bethesda, Maryland 20892 |
Department of Health and Human Services (HHS) |
||||||||
Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, Audio or Video files, see Help Downloading Files. |